NCT06740539尚未招募不适用
Atrial Fibrillation with Heart Failure with Preserved Ejection Fraction: Treatment Strategies-Catheter Ablation Vs. Anti-Atrial Arrhythmia Drugs
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 304
- 试验地点
- 1
- 主要终点
- The primary endpoint was a composite of all-cause death or rehospitalization for worsening HF.
研究概览
简要总结
A comparison of whether catheter ablation improves the prognosis (all-cause mortality and/or the composite endpoint of MACE) and reduces the recurrence rate of atrial fibrillation (AF) in patients with AF and heart failure with preserved ejection fraction (HFpEF), compared to anti-atrial arrhythmia drugs (AAD). This trial was randomly divided into two groups: the anti-AAD drug group and the catheter ablation group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years.
- •The patient is willing and able to comply with the protocol and has provided written informed consent.
- •Paroxysmal or persistent atrial fibrillation (AF).（Persistent AF was defined as AF which is sustained beyond 7 days, or lasting less than seven days but necessitating pharmacologic or electric cardioversion. Included within the category of persistent AF is 'long-standing persistent AF', defined as continuous AF of >1-year duration. AF episodes had to be documented in the last 3 months prior to enrollment by ECG, Holter ECG, Loop Recorder, memory of the implanted device (ICD/CRT-D), or any other suitable device.）
- •Failure or intolerance of antiarrhythmic drug therapy or unwillingness to take antiarrhythmic drugs.
- •Diagnosed with Heart Failure with Preserved Ejection Fraction (HFpEF).（(1) a history of hospitalization for HF with symptoms classified as New York Heart Association (NYHA) class II, III, or IV; (2) LVEF ≥ 50%; (3) at least one of the following cardiac structural abnormalities identified by echocardiography: left ventricular hypertrophy, left atrial enlargement, or diastolic dysfunction; and (4) elevated levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), with a threshold of ≥400 pg/mL for pa-tients with SR at admission and ≥600 pg/mL for patients with AF at admis-sion.)
- •New York Heart Association class II, III, or IV.
排除标准
- •Previous left heart ablation procedure for AF.
- •Contraindication to chronic anticoagulation therapy or heparin.
- •Documented left atrial diameter >6 cm, optimally from the parasternal long-axis view.
- •Acute coronary syndrome, cardiac surgery, angioplasty, or cerebrovascular accident within 2 months prior to enrollment.
- •Planned cardiovascular intervention.
- •Listed for heart transplant.
- •Cardiac assist device implanted.
- •Life expectancy ≤ 12 months.
- •Mental or physical inability to participate in the study.
- •Requirement for dialysis due to terminal renal failure.
- •Woman currently pregnant or breastfeeding or not using reliable contraceptive measures during fertility age.
- •Enrollment in another investigational drug or device study, or participation in another telemonitoring concept.
研究组 & 干预措施
Ablation Group
Experimental
Ablation Group: Received heart failure treatment combined with ablation
干预措施: Catheter ablation of atrial fibrillation (Procedure)
Drug Control Group
No Intervention
Received heart failure treatment combined with heart rate control.
结局指标
主要结局
The primary endpoint was a composite of all-cause death or rehospitalization for worsening HF.
时间窗: During regular follow-up visits at 3, 6, 12, 24months.
The primary endpoint was a composite of all-cause death or rehospitalization for worsening HF.
次要结局
- All-Cause Mortality(During regular follow-up visits at 3, 6, 12, 24months.)
- Worsening of Heart Failure Requiring Unplanned Hospitalization(During regular follow-up visits at 3, 6, 12, 24months.)
- Cardiovascular Mortality(During regular follow-up visits at 3, 6, 12, 24months.)
- Unplanned Hospitalization due to Cardiovascular Reason(During regular follow-up visits at 3, 6, 12, 24months.)
- All-Cause Hospitalization(During regular follow-up visits at 3, 6, 12, 24months.)
- Cerebrovascular Accident(During regular follow-up visits at 3, 6, 12, 24months.)
研究者
Xu Liu
Professor
Shanghai Chest Hospital
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Catheter Ablation Versus Medical Treatment of AF in Heart FailureAtrial FibrillationHeart FailureNCT01411371Barts & The London NHS Trust50
已完成
不适用
Catheter Ablation for Atrial Fibrillation in patientS With End-sTage Heart Failure and Eligibility for Heart TransplantationHeart FailureAtrial FibrillationNCT04649801Heart and Diabetes Center North-Rhine Westfalia194
终止
不适用
Cryoballoon Ablation Versus Medical Therapy in Patients With Heart Failure and Atrial FibrillationHeart Failure, SystolicHeart Failure With Reduced Ejection FractionHeart FailureAtrial FibrillationNCT04342832Maastricht University64
撤回
4 期
Catheter Ablation for Recently Diagnosed Paroxysmal Atrial FibrillationAtrial FibrillationNCT01505296Valley Health System
招募中
不适用
Catheter Ablation in Atrial Fibrillation Patients With HFpEF (STABLE-SR IV Trial)HFpEF - Heart Failure With Preserved Ejection FractionAtrial FibrillationNCT06125925The First Affiliated Hospital with Nanjing Medical University436